Myomo, Inc. (MYO) Stock Analysis and Metrics

Myomo

NYSE: MYO

$0.99 ▼ -0.01 (-1.24%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap39.24 Mn

P/E-3.66

Div. Yield0.00

Total Debt (Qtr)13.96 Mn

Add ratio to table…

About

Myomo, Inc. is a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The company develops and markets the MyoPro product line, a myoelectric-controlled upper limb brace or orthosis designed to support a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living in the home and community. The MyoPro is custom-fabricated by trained professionals for each individual user to meet their specific needs and is designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders.

Myomo generates revenue primarily through the sale of its MyoPro devices, which are custom-fabricated limb orthoses. The company bills insurance companies directly under its direct billing channel when providing devices to patients, and also sells through orthotics and prosthetics (O&P) providers, the Veterans Administration, and certain international accounts. Revenue is derived from two HCPCS codes: L8701 (Motion W, a multi-articulated non-powered wrist) and L8702 (Motion G, which includes a powered grasp), with the majority of devices billed under L8702. The company also earns revenue from associated clinical services such as evaluation, measurement, fitting, and training when acting as the provider in the direct billing model.

The company operates through the following segments:

• MyoPro Product Line: This segment encompasses the development, manufacturing, and commercialization of the MyoPro custom fabricated limb orthosis. The MyoPro is a myoelectric-controlled upper limb brace that supports weak or paralyzed arms and helps improve functional activities of daily living. The device consists of a portable arm brace made of lightweight metal and includes advanced signal processing software, non-invasive sensors, small motors, a lightweight battery unit, and 3D printed materials unique to each patient's arm and hand measurements. The segment also includes the MyoPal device for pediatric use, which is part of the product roadmap for future release after the MyoPro3. The MyoPro2x, introduced in April 2025, incorporates more intuitive donning, 3D printed orthotics capability, and software enhancements. The flagship MyoPro 2, introduced in June 2017, features improvements in control technology, new configuration software and user interface, and a longer-lasting, pop-out battery. The MyoPro Motion G product, which allows for movement of multiple joints, generated 96% of product revenue for the year ended December 31, 2025. The segment holds 35 issued patents in the United States and various countries, with 14 pending patent applications, and trademarks including Myomo, MyoPro, MyoPal, MyoCare, and MyoCoach are registered with the U. S. Patent & Trademark Office and in other countries.

Myomo holds a leading position in the niche market of myoelectric limb orthotics for upper extremity paralysis, believing it is the only device commercially available in the United States that helps neuromuscular-impaired individuals regain movement in weak arms and hands using their own muscle signals after therapy. The company faces limited direct competition in this specialized space, with potential alternatives including non-powered braces, rehabilitation therapy, and emerging exoskeleton suits for upper extremity use, though few companies focus specifically on powered orthotics for paralyzed arms. Myomo's competitive advantages stem from its patented EMG control technology, first-mover advantage in the U. S., international presence in Germany and the United Kingdom, and its ability to provide a custom-fabricated, lightweight orthosis that enables self-initiated movement through detected muscle signals without stimulation. The company's intellectual property, including 35 issued patents and trade secrets from over ten years of R&D, supports its market leadership goal.

Myomo serves patients with neuromuscular conditions affecting upper limb function, including those recovering from stroke, brachial plexus injury, spinal cord injury, traumatic brain injury, cerebral palsy, and other neurological disorders. The company works with healthcare providers such as the Cleveland Clinic, Spaulding Rehabilitation Hospital, Loma Linda University Medical Center, Kennedy Krieger Institute, University of Utah, and numerous VA Medical Centers for referrals and clinical collaboration. Myomo also partners with orthotics and prosthetics providers, bills insurance companies directly including Medicare and Medicare Advantage plans, and engages with private health insurers for reimbursement. The company's patient pipeline includes individuals seeking insurance authorization for MyoPro devices, with 1,528 patients in the reimbursement pipeline as of December 31, 2025.

Investment Thesis

▲ Bull case

Myomo’s strategic pivot toward recurring patient sources represents a fundamental shift in business model that is significantly underappreciated by the market. The company’s emphasis on reducing dependence on high-cost advertising-driven acquisition in favor of lower-cost referral channels through programs like MyoConnect and partnerships with insurers such as Elevance Health directly addresses the core challenge of scaling in a fragmented healthcare market. In Q1 2026, recurring patient sources represented 49% of revenue, up from 25% a year ago, while direct billing referrals accounted for 11% of pipeline adds and 16% of orders—signaling early traction in a higher-margin, more sustainable growth engine. This transition is further reinforced by the appointment of Will Febbo, whose track record at OptimizeRx—where he scaled revenue from $5 million to $92 million with a 41% CAGR and led an OTC-to-Nasdaq uplisting—provides credible expertise in scaling direct-to-patient healthcare platforms. His background in capital markets and digital healthcare networks positions him to amplify Myomo’s visibility among institutional investors and accelerate payer adoption, which remains a critical lever for broadening access to MyoPro devices. The market is underestimating how this strategic realignment could structurally lower customer acquisition costs over time while increasing lifetime value per patient, especially as the company leverages data from the MyoMobile App to improve clinical outcomes and retention. With operating leverage expected to improve as expense growth trails revenue growth in 2026, this shift could unlock meaningful margin expansion that is not yet reflected in current valuations. Myomo
The launch of the Myomo Mobile App introduces a powerful, under-discussed catalyst for long-term differentiation and data-driven value creation beyond hardware sales. By enabling real-time EMG signal tracking, remote clinician adjustments, and patient engagement tools, the app transforms MyoPro from a standalone orthotic device into a connected care platform capable of generating proprietary usage and outcomes data. This data asset has significant untapped potential to support reimbursement negotiations with payers, inform R&D for next-generation iterations, and create opportunities for subscription-based services or outcomes-based pricing models—avenues management has hinted at but not yet fully monetized. Clinicians gain visibility into patient adherence and device performance, facilitating proactive follow-up and reducing dropout rates, while patients receive feedback that boosts confidence and self-management—key factors in improving functional outcomes and word-of-mouth referrals. The app’s availability on both iOS and Android platforms ensures broad accessibility, and its integration into clinical workflows positions Myomo to capture network effects as more providers adopt it. Unlike the device itself, which faces reimbursement and awareness barriers, the software layer can scale with minimal marginal cost and create switching barriers for both patients and clinicians. The market is overlooking how this digital wrapper could evolve into a recurring revenue stream and defensible moat, particularly as Myomo expands into value-based care arrangements where demonstrable improvement in patient function directly impacts payment eligibility. Myomo
Myomo’s expanding insurance footprint through network participation agreements with major payers like Elevance Health—covering 45 million lives and bringing total covered lives to over 80 million—is a structural catalyst that remains insufficiently priced into the stock. These agreements are not merely incremental access improvements; they represent a systemic de-risking of adoption by embedding MyoPro into established clinical pathways within large, national health plans. The effectiveness of these contracts on a market-by-market basis through Q2 2026 suggests a predictable rollout trajectory, with reimbursement certainty reducing a major barrier for both patients and providers. Crucially, this expansion aligns with Myomo’s stated success pillar of increasing market access while simultaneously supporting its shift toward lower-cost recurring patient sources, as insurer-covered patients typically exhibit higher adherence and lower churn. The company’s unique position as the only FDA-cleared device in the U.S. that uses non-invasive EMG sensing to restore functional movement in paralysis creates a natural monopoly in its niche, and broadening payer coverage directly translates to addressable market expansion without requiring new product development. Management’s guidance for 2026 revenue of $43–46 million implies meaningful upside if even a fraction of the newly covered lives convert to users, especially given the aging population and rising stroke incidence. The market is failing to fully appreciate how this access expansion, combined with improving clinical validation and referral dynamics, could drive a multi-year inflection in adoption rates that exceeds current linear growth expectations. Myomo

Myomo’s strategic pivot toward recurring patient sources represents a fundamental shift in business model that is significantly underappreciated by the market. The company’s emphasis on reducing dependence on high-cost advertising-driven acquisition in favor of lower-cost referral channels through programs like MyoConnect and partnerships with insurers such as Elevance Health directly addresses the core challenge of scaling in a fragmented healthcare market. In Q1 2026, recurring patient sources represented 49% of revenue, up from 25% a year ago, while direct billing referrals accounted for 11% of pipeline adds and 16% of orders—signaling early traction in a higher-margin, more sustainable growth engine. This transition is further reinforced by the appointment of Will Febbo, whose track record at OptimizeRx—where he scaled revenue from $5 million to $92 million with a 41% CAGR and led an OTC-to-Nasdaq uplisting—provides credible expertise in scaling direct-to-patient healthcare platforms. His background in capital markets and digital healthcare networks positions him to amplify Myomo’s visibility among institutional investors and accelerate payer adoption, which remains a critical lever for broadening access to MyoPro devices. The market is underestimating how this strategic realignment could structurally lower customer acquisition costs over time while increasing lifetime value per patient, especially as the company leverages data from the MyoMobile App to improve clinical outcomes and retention. With operating leverage expected to improve as expense growth trails revenue growth in 2026, this shift could unlock meaningful margin expansion that is not yet reflected in current valuations. Myomo
The launch of the Myomo Mobile App introduces a powerful, under-discussed catalyst for long-term differentiation and data-driven value creation beyond hardware sales. By enabling real-time EMG signal tracking, remote clinician adjustments, and patient engagement tools, the app transforms MyoPro from a standalone orthotic device into a connected care platform capable of generating proprietary usage and outcomes data. This data asset has significant untapped potential to support reimbursement negotiations with payers, inform R&D for next-generation iterations, and create opportunities for subscription-based services or outcomes-based pricing models—avenues management has hinted at but not yet fully monetized. Clinicians gain visibility into patient adherence and device performance, facilitating proactive follow-up and reducing dropout rates, while patients receive feedback that boosts confidence and self-management—key factors in improving functional outcomes and word-of-mouth referrals. The app’s availability on both iOS and Android platforms ensures broad accessibility, and its integration into clinical workflows positions Myomo to capture network effects as more providers adopt it. Unlike the device itself, which faces reimbursement and awareness barriers, the software layer can scale with minimal marginal cost and create switching barriers for both patients and clinicians. The market is overlooking how this digital wrapper could evolve into a recurring revenue stream and defensible moat, particularly as Myomo expands into value-based care arrangements where demonstrable improvement in patient function directly impacts payment eligibility. Myomo
Myomo’s expanding insurance footprint through network participation agreements with major payers like Elevance Health—covering 45 million lives and bringing total covered lives to over 80 million—is a structural catalyst that remains insufficiently priced into the stock. These agreements are not merely incremental access improvements; they represent a systemic de-risking of adoption by embedding MyoPro into established clinical pathways within large, national health plans. The effectiveness of these contracts on a market-by-market basis through Q2 2026 suggests a predictable rollout trajectory, with reimbursement certainty reducing a major barrier for both patients and providers. Crucially, this expansion aligns with Myomo’s stated success pillar of increasing market access while simultaneously supporting its shift toward lower-cost recurring patient sources, as insurer-covered patients typically exhibit higher adherence and lower churn. The company’s unique position as the only FDA-cleared device in the U.S. that uses non-invasive EMG sensing to restore functional movement in paralysis creates a natural monopoly in its niche, and broadening payer coverage directly translates to addressable market expansion without requiring new product development. Management’s guidance for 2026 revenue of $43–46 million implies meaningful upside if even a fraction of the newly covered lives convert to users, especially given the aging population and rising stroke incidence. The market is failing to fully appreciate how this access expansion, combined with improving clinical validation and referral dynamics, could drive a multi-year inflection in adoption rates that exceeds current linear growth expectations. Myomo

▼ Bear case

Myomo’s core business remains heavily dependent on volatile, high-cost customer acquisition channels that are proving increasingly inefficient, casting doubt on the sustainability of its recent revenue growth. Despite management’s narrative about shifting to recurring patient sources, the company still allocated significant resources to advertising in Q1 2026, with selling, clinical, and marketing expenses rising 10% year-over-year to $4.8 million, partially offsetting reductions in R&D and G&A. The cost per pipeline add, while down 16% sequentially, remains 11% higher than a year ago at $2,550, indicating that the benefits of new marketing programs and agency partnerships have yet to materialize at scale. More troubling is the persistent decline in unit volume: Myomo recognized revenue on only 172 MyoPro units in Q1 2026, down 5% from the prior year, even as ASP increased 9% to $58,800—suggesting the company is relying on price increases rather than volume growth to drive revenue, a strategy that is inherently limited in a price-sensitive reimbursement environment. This trend raises concerns about market saturation among early adopters and the difficulty of penetrating broader patient populations without breakthrough improvements in awareness, clinician education, or reimbursement pathways. The company’s continued operating losses—$3.2 million in Q1 2026—and negative adjusted EBITDA of $(2.3) million underscore that it remains far from profitability, with no clear path to breakeven under current unit economics. Myomo
Gross margin erosion continues to signal underlying weakness in Myomo’s cost structure and pricing power, despite temporary improvements driven by ASP fluctuations. While Q1 2026 gross margin rose to 68.2% from 67.2% in Q1 2025 due to higher ASP, the full-year 2025 margin deteriorated to 65.7% from 71.2% in 2024—a decline driven by lower ASP, unfavorable inventory overhead absorption, and higher warranty costs. This pattern reveals a business model under pressure, where increasing competition, discounting to win tenders, or rising component and logistics costs are undermining profitability even as the company attempts to premium-price its devices. The reliance on ASP expansion to offset volume declines is unsustainable in the long term, particularly as MyoPro faces potential future competition from emerging exoskeleton and neuroprosthetic technologies that could offer superior functionality at lower cost. Furthermore, the capitalization of overhead into inventory—cited as a factor in gross margin fluctuations—introduces accounting complexity and potential volatility, making true profitability harder to discern. Management has not provided a clear roadmap for how it will structurally improve margins through scale, supply chain optimization, or cost-reducing design changes, leaving investors exposed to the risk that current gross margin levels represent a ceiling rather than a floor. Myomo
Myomo’s financial condition remains fragile, with deteriorating liquidity and rising leverage creating significant downside risk that the market is overlooking amid optimistic narratives about future growth. Cash, cash equivalents, and short-term investments declined to $15.7 million as of March 31, 2026, from $18.4 million at December 31, 2025, reflecting continued cash burn despite claims of improving operating leverage. The company used $2.2 million in cash from operating activities in Q1 2026, and while this was an improvement from $2.7 million in the prior year, it still underscores persistent negative cash flow from core operations. More alarmingly, long-term debt remains substantial at $10.9 million as of March 31, 2026, following the refinancing of its debt facility with Avenue Capital—a move that involved one-time expenses, interest costs, and derivative liabilities that contributed to non-operating losses in Q4 2025. The warrant derivative liability, though reduced from $1.0 million to $718,540, remains a source of balance sheet volatility and potential dilution risk. With accumulated deficit now exceeding $121.7 million and stockholders’ equity falling to $9.0 million from $11.4 million at year-end 2025, Myomo has minimal cushion to absorb setbacks in reimbursement delays, slower-than-expected payer contract rollouts, or unexpected regulatory hurdles. The company’s reliance on continued access to capital markets—bolstered by new board members with capital markets expertise—suggests awareness of this fragility, but until operating cash flow turns meaningfully positive, the risk of a dilutive financing event or covenant breach remains materially underappreciated. Myomo

Myomo’s core business remains heavily dependent on volatile, high-cost customer acquisition channels that are proving increasingly inefficient, casting doubt on the sustainability of its recent revenue growth. Despite management’s narrative about shifting to recurring patient sources, the company still allocated significant resources to advertising in Q1 2026, with selling, clinical, and marketing expenses rising 10% year-over-year to $4.8 million, partially offsetting reductions in R&D and G&A. The cost per pipeline add, while down 16% sequentially, remains 11% higher than a year ago at $2,550, indicating that the benefits of new marketing programs and agency partnerships have yet to materialize at scale. More troubling is the persistent decline in unit volume: Myomo recognized revenue on only 172 MyoPro units in Q1 2026, down 5% from the prior year, even as ASP increased 9% to $58,800—suggesting the company is relying on price increases rather than volume growth to drive revenue, a strategy that is inherently limited in a price-sensitive reimbursement environment. This trend raises concerns about market saturation among early adopters and the difficulty of penetrating broader patient populations without breakthrough improvements in awareness, clinician education, or reimbursement pathways. The company’s continued operating losses—$3.2 million in Q1 2026—and negative adjusted EBITDA of $(2.3) million underscore that it remains far from profitability, with no clear path to breakeven under current unit economics. Myomo
Gross margin erosion continues to signal underlying weakness in Myomo’s cost structure and pricing power, despite temporary improvements driven by ASP fluctuations. While Q1 2026 gross margin rose to 68.2% from 67.2% in Q1 2025 due to higher ASP, the full-year 2025 margin deteriorated to 65.7% from 71.2% in 2024—a decline driven by lower ASP, unfavorable inventory overhead absorption, and higher warranty costs. This pattern reveals a business model under pressure, where increasing competition, discounting to win tenders, or rising component and logistics costs are undermining profitability even as the company attempts to premium-price its devices. The reliance on ASP expansion to offset volume declines is unsustainable in the long term, particularly as MyoPro faces potential future competition from emerging exoskeleton and neuroprosthetic technologies that could offer superior functionality at lower cost. Furthermore, the capitalization of overhead into inventory—cited as a factor in gross margin fluctuations—introduces accounting complexity and potential volatility, making true profitability harder to discern. Management has not provided a clear roadmap for how it will structurally improve margins through scale, supply chain optimization, or cost-reducing design changes, leaving investors exposed to the risk that current gross margin levels represent a ceiling rather than a floor. Myomo
Myomo’s financial condition remains fragile, with deteriorating liquidity and rising leverage creating significant downside risk that the market is overlooking amid optimistic narratives about future growth. Cash, cash equivalents, and short-term investments declined to $15.7 million as of March 31, 2026, from $18.4 million at December 31, 2025, reflecting continued cash burn despite claims of improving operating leverage. The company used $2.2 million in cash from operating activities in Q1 2026, and while this was an improvement from $2.7 million in the prior year, it still underscores persistent negative cash flow from core operations. More alarmingly, long-term debt remains substantial at $10.9 million as of March 31, 2026, following the refinancing of its debt facility with Avenue Capital—a move that involved one-time expenses, interest costs, and derivative liabilities that contributed to non-operating losses in Q4 2025. The warrant derivative liability, though reduced from $1.0 million to $718,540, remains a source of balance sheet volatility and potential dilution risk. With accumulated deficit now exceeding $121.7 million and stockholders’ equity falling to $9.0 million from $11.4 million at year-end 2025, Myomo has minimal cushion to absorb setbacks in reimbursement delays, slower-than-expected payer contract rollouts, or unexpected regulatory hurdles. The company’s reliance on continued access to capital markets—bolstered by new board members with capital markets expertise—suggests awareness of this fragility, but until operating cash flow turns meaningfully positive, the risk of a dilutive financing event or covenant breach remains materially underappreciated. Myomo

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password